Cystic Fibrosis
Spirovant Sciences Doses First Patient in Phase 1/2 Trial of Its Aerosol-Delivered Genetic Medicine for Treating Cystic Fibrosis
Spirovant Sciences
PR-11-24-NI-101Nov 15, 2024
Cystic Fibrosis
Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
Aridis Pharmaceuticals, Inc.
PR-M12-18-NI-013Dec 05, 2018
FDA Approval
FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene
Vertex
PR-M09-18-NI-050Sep 19, 2018
FDA Approval
FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease
Vertex
PR-M08-18-NI-075Aug 20, 2018
Partnership
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership
Boehringer Ingelheim
PR-M08-18-NI-049Aug 13, 2018